Dosing

Taltz dosing for patients with moderate to severe plaque psoriasis1

The dosing regimen is the same for adult patients with moderate to severe plaque psoriasis and for adult patients with psoriatic arthritis* and coexistent moderate to severe plaque psoriasis

Taltz dosing for plaque psoriasis


Reminders1,5

  • If patients forget to take their Taltz dose, instruct them to inject a dose as soon as they remember; then to take their next dose at the regularly scheduled time

For detailed administration instructions, please have patients read the Instructions for Use included with the device.

TALTZ is intended for use under the guidance and supervision of a physician. Patients may self-inject after training in the proper technique. Evaluate patients for tuberculosis prior to initiating treatment with TALTZ.

Taltz dosing for patients with psoriatic arthritis1

Taltz dosing for psoriatic arthritis

For patients with psoriatic arthritis and coexistent moderate to severe plaque psoriasis, follow the plaque psoriasis dosing.

If patients forget to take their Taltz dose, instruct them to inject a dose as soon as they remember; then to take their next dose at the regularly scheduled time.

For detailed administration instructions, please have patients read the Instructions for Use included with the device.

TALTZ is intended for use under the guidance and supervision of a physician. Patients may self-inject after training in the proper technique. Evaluate patients for tuberculosis prior to initiating treatment with TALTZ.

Just a 1-day starting dose followed by a once-monthly* schedule

Taltz dosing for ankylosing spondylitis

*Every 4 weeks.

Starting dose of two 80 mg injections, followed by one 80 mg injection every 4 weeks thereafter.

The dosing regimen is the same for adult patients with ankylosing spondylitis and for adult patients with psoriatic arthritis without coexistent moderate to severe plaque psoriasis.

If patients forget to take their Taltz dose, instruct them to inject a dose as soon as they remember; then, to take their next dose at the regularly scheduled time.

TALTZ is intended for use under the guidance and supervision of a physician. Patients may self-inject after training in the proper technique. Evaluate patients for tuberculosis prior to initiating treatment with TALTZ.

Devices



Taltz has 2 device options, offering you the flexibility to choose the one that best suits your patients1,6

Devices designed with patients in mind

Dosing devices

At first use, over 94% of patients with moderate to severe plaque psoriasis agreed the Taltz autoinjector was “easy to use” and were confident in their ability to use it.

Please see Instructions for Use included with the device.

Device study trial design


References: 1. Taltz [package insert]. Indianapolis, IN: Eli Lilly and Company; 2019. 2. Martin DA, Towne JE, Kricorian G, et al. The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. J Invest Dermatol. 2013:133:17-26. 3. Kirkham BW, Kavanaugh A, Reich K. Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis. Immunology. 2013;141:133-142. 4. Paul C. Ixekizumab or secukinumab in psoriasis: what difference does it make? Br J Dermatol. 2018;178:1003-1005. 5. Taltz [instructions for use]. Indianapolis, IN: Eli Lilly and Company; 2018. 6. Callis Duffin K, Bukhalo M, Bobonich MA, et al. Usability of a novel disposable autoinjector device for ixekizumab: results from a qualitative study and an open-label clinical trial, including patient-reported experience. Med Devices (Auckl). 2016;9:361-369.

Indications and Important Safety Information
Indications

Taltz is indicated for your adult patients with active psoriatic arthritis (PsA) and active ankylosing spondylitis (AS).

Taltz is also indicated for your adult patients with moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy.

Important Safety Information
CONTRAINDICATIONS
Taltz is contraindicated in patients with a previous serious hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients.

WARNINGS AND PRECAUTIONS
Infections
Taltz may increase the risk of infection. In clinical trials of patients with plaque psoriasis, the Taltz group had a higher rate of infections than the placebo group (27% vs 23%). A similar increase in risk of infection was seen in placebo-controlled trials of patients with psoriatic arthritis and ankylosing spondylitis. Serious infections have occurred. Instruct patients to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a serious infection develops, discontinue Taltz until the infection resolves.

Pre-Treatment Evaluation for Tuberculosis
Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with Taltz. Do not administer to patients with active TB infection. Initiate treatment of latent TB prior to administering Taltz. Closely monitor patients receiving Taltz for signs and symptoms of active TB during and after treatment.

Hypersensitivity
Serious hypersensitivity reactions, including angioedema and urticaria (each ≤0.1%), occurred in the Taltz group in clinical trials. Anaphylaxis, including cases leading to hospitalization, has been reported in post-marketing use with Taltz. If a serious hypersensitivity reaction occurs, discontinue Taltz immediately and initiate appropriate therapy.

Inflammatory Bowel Disease
During Taltz treatment, monitor patients for onset or exacerbations of inflammatory bowel disease. Crohn’s disease and ulcerative colitis, including exacerbations, occurred at a greater frequency in the Taltz 80 mg Q2W group (Crohn’s disease 0.1%, ulcerative colitis 0.2%) than in the placebo group (0%) during clinical trials in patients with plaque psoriasis and in the Taltz Q4W group in ankylosing spondylitis trials (Crohn’s disease 1.0% [2 patients], ulcerative colitis 0.5% [1 patient]) than in the placebo group (Crohn’s disease 0.5% [1 patient], ulcerative colitis 0%). In the ankylosing spondylitis trials, serious events occurred in 1 patient in the Taltz group and 1 patient in the placebo group.

Immunizations
Prior to initiating therapy with Taltz, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with Taltz.

ADVERSE REACTIONS
Most common adverse reactions (≥1%) associated with Taltz treatment are injection site reactions, upper respiratory tract infections, nausea, and tinea infections. Overall, the safety profiles observed in patients with psoriatic arthritis and ankylosing spondylitis were consistent with the safety profile in patients with plaque psoriasis, with the exception of influenza and conjunctivitis in psoriatic arthritis.

Please click to access the Prescribing Information and Medication Guide. Please see Instructions for Use included with the device.
IX HCP ISI 23AUG2019